Poison center calls on bootleg retatrutide reach 862 as FDA logs two deaths
Exposures nearly doubled from 460 in the prior quarter, while two FDA adverse event reports describe cardiac arrest deaths after use of online-sourced retatrutide.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 14 03:28 ETSource: Medical Daily
The wire
- 01America's Poison Centers recorded 862 retatrutide exposures in the three months to September, up from 460 and 249 in the two preceding quarters; FDA received two death reports via FAERS.
- 02One report describes a 49-year-old who died after dehydration, malnutrition and cardiac arrest, with a nurse said to have sold her vials from an online peptide vendor and advised dosing.
- 03Causality is unestablished and the FDA declined to say whether it verified the reports; retatrutide remains an unapproved Lilly investigational drug studied at 28.3% mean weight loss in TRIUMPH-1.
From the source
Read at medicaldaily.comPoison Center Exposures to Bootleg Retatrutide Nearly Double in Three Months as FDA Logs Two Death Reports
America's Poison Centers logged 862 exposures to retatrutide in the three months ending in September, up from 460 in the prior three months and 249 in the first three months of 2026, CBS News reported . The FDA has also received two reports of people who died after taking products sold as retatrutide, an experimental Eli Lilly obesity drug that no regulator has approved.
